Acorah Software Products - Accounts Production 16.8.310 false true 30 April 2024 1 May 2023 false 1 May 2024 30 April 2025 30 April 2025 12100172 Mr Sheraz Khan Mr Shahzad Khan iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12100172 2024-04-30 12100172 2025-04-30 12100172 2024-05-01 2025-04-30 12100172 frs-core:CurrentFinancialInstruments 2025-04-30 12100172 frs-core:Non-currentFinancialInstruments 2025-04-30 12100172 frs-core:ShareCapital 2025-04-30 12100172 frs-core:RetainedEarningsAccumulatedLosses 2025-04-30 12100172 frs-bus:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 12100172 frs-bus:FilletedAccounts 2024-05-01 2025-04-30 12100172 frs-bus:SmallEntities 2024-05-01 2025-04-30 12100172 frs-bus:AuditExempt-NoAccountantsReport 2024-05-01 2025-04-30 12100172 frs-bus:SmallCompaniesRegimeForAccounts 2024-05-01 2025-04-30 12100172 frs-core:CostValuation 2024-04-30 12100172 frs-core:CostValuation 2025-04-30 12100172 frs-core:ProvisionsForImpairmentInvestments 2024-04-30 12100172 frs-core:ProvisionsForImpairmentInvestments 2025-04-30 12100172 frs-bus:Director1 2024-05-01 2025-04-30 12100172 frs-bus:Director2 2024-05-01 2025-04-30 12100172 frs-countries:EnglandWales 2024-05-01 2025-04-30 12100172 2023-04-30 12100172 2024-04-30 12100172 2023-05-01 2024-04-30 12100172 frs-core:CurrentFinancialInstruments 2024-04-30 12100172 frs-core:Non-currentFinancialInstruments 2024-04-30 12100172 frs-core:ShareCapital 2024-04-30 12100172 frs-core:RetainedEarningsAccumulatedLosses 2024-04-30
Registered number: 12100172
Naylor Pharma LTD
Unaudited Financial Statements
For The Year Ended 30 April 2025
UK Tax Accountants
89 Jacobs Well Lane
Wakefield
WF1 3PB
Naylor Pharma LTD
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—4

Page 1
Naylor Pharma LTD
Balance Sheet
As At 30 April 2025
Balance Sheet
Registered number: 12100172

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Investments | 4 |  | 540,482 |  | 540,482
|  |  | 540,482 |  | 540,482
CURRENT ASSETS
Cash at bank and in hand |  | 100 |  | 100 |
|  | 100 |  | 100 |
Creditors: Amounts Falling Due Within One Year | 5 | (52,606 ) |  | (52,006 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | (52,506 ) |  | (51,906 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 487,976 |  | 488,576
Creditors: Amounts Falling Due After More Than One Year | 6 |  | (317,247 ) |  | (357,479 )
NET ASSETS |  |  | 170,729 |  | 131,097
CAPITAL AND RESERVES
Called up share capital | 7 |  | 100 |  | 100
Profit and Loss Account |  |  | 170,629 |  | 130,997
SHAREHOLDERS' FUNDS |  |  | 170,729 |  | 131,097

Page 1
Page 2
Naylor Pharma LTD
Balance Sheet (continued)
As At 30 April 2025
For the year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Mr Sheraz Khan Director
21st January 2026

The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Naylor Pharma LTD
Notes to the Financial Statements
For The Year Ended 30 April 2025
Notes to the Financial Statements
1. General Information
Naylor Pharma LTD is a private company, limited by shares, incorporated in England & Wales, registered number 12100172 . The registered office is 40-42 Market Place, Knaresborough, HG5 8AG.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2024: NIL)
- -
4. Investments

| Other
--- | ---
| £
Cost or Valuation
As at 1 May 2024 | 540,482
As at 30 April 2025 | 540,482
Provision
As at 1 May 2024 | -
As at 30 April 2025 | -
Net Book Value
As at 30 April 2025 | 540,482
As at 1 May 2024 | 540,482

5. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Accruals and deferred income | 600 |  | -
Directors' loan accounts | 52,006 |  | 52,006
| 52,606 |  | 52,006

6. Creditors: Amounts Falling Due After More Than One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Bank loans | 296,815 |  | 326,257
Other loans | 20,432 |  | 31,222
| 317,247 |  | 357,479

Page 3
Page 4
Naylor Pharma LTD
Notes to the Financial Statements (continued)
For The Year Ended 30 April 2025
7. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 100 |  | 100

Page 4